I think it is the low float of 15 million tradable shares that makes this stock move up quickly, supply and demand, plus insain future profits.
Does that mean that all the hospitals in Germany will get Cytosorb filters because of the connection with Fresenius or will they have to go over the boarder to get them from their neighboring countries .
If you saw the news today with CTSO and their partnership with Fresenius Medical Care , some people could be hedging their bets here at AEMD
It will be very hard for bashers to deny this straight up statement (The shares of Common Stock have been approved for listing on NASDAQ Capital Market (the “Exchange”),
:NEW YORK, NY - DECEMBER 09: Prince William, Duke of Cambridge presents an award to Phillip Chan of CytoSorbents Corporation during the Innovation is GREAT Reception at Shutterstock headquarters in the Empire State Building on December 9, 2014 in New York City. The reception was technology themed and the winners of the GREAT Tech Awards were presented with trophies
NASA licensed its patented invention of the year to an American company , This electronic nose that can sense a complete array of chemicals ,they are working on a cancer detection sensor using the breath , they are working with Scripps mhealth , Vantage health inc. is the company, VNTH is the stock symbol ,they are and American company that will produce the product in American per licence agreement from NASA, 82% of the company is held by insiders, low float , company is working under the radar , the people on board are amazing check them out,
Recently, molecular samples analyzed by the Vantage Sensor 2.0 were sent to a third party laboratory specializing in analytical, environmental and pharmacological testing. When testing for lower and higher concentrations of certain molecules, which are important biomarkers in disease detection, results suggested that the sensor may actually be more sensitive than Gas Chromatography–Mass Spectrometry (GC-MS). A GC-MS is considered the gold standard for molecular analysis typically costing as much as six figures. Vantage plans to retail this sensor for less than $200
Heart surgery patients who received newly donated blood have significantly fewer post-operative complications than those who received blood that had been donated more than two weeks before their surgery, a study presented at the Canadian Cardiovascular Congress has shown.
The study examined records at the New Brunswick Heart Centre (NBHC) in Saint John for non-emergency heart surgeries performed over almost nine years, from January 2005 to September 2013, on patients who received red blood cells either during their surgery or afterwards and who stayed in hospital less than 30 days.
Of 2,015 patients, just over half (1,052) received only "new" blood, donated within 14 days of the transfusion, while the rest had received only or some "old" blood, donated more than 14 days before. Canadian protocols allow blood to be stored and used up to six weeks after it is donated.
After adjusting for differences in age, sex and other health conditions between the two groups of patients, the study found those given only new blood had fewer in-hospital complications such as re-operation for bleeding, ventilation longer than 24 hours, infection, renal failure and death. Overall the patients who received new blood fared significantly better than those who received some or all old blood.
"The findings show that we need to pay attention to the age of the blood we give cardiac surgery patients," says Dr. Ansar Hassan of the department of cardiac surgery at NBHC, the study's senior author.
Given the benefits to patients of timely cardiac surgery, Dr. Hassan believes surgeries should not be postponed if new blood is not available. "Perhaps more importantly, we need new studies to determine what is driving this relationship between the age of blood and the outcomes we are seeing." Dr. Hassan notes that previous non-Canadian studies have reached contradictory conclusions on this subject, which was a reason this study was undertaken. The question is important to cardiac surgeons
Biocon will continue to market CytoSorb ® with their critical care antibiotics as
the “most comprehensive treatment” of sepsis
• Biocon has also agreed to an increase in annual minimum sales targets which
should result in significantly increased sales over the life of the agreement
No, just cut and pasted from someone else post ,you don't learn do you, now I am going to cut and past it on the AEMD yahoo board ,not very smart are you.
You are correct CTSO is selling and making money now not in 3 to 5 years from now unlike AETH and a 100 other biotechnology companies that are trading at ridiculous PE with no money or means to make. I said it before CTSO will be my retirement bank .
Vantage Health Inc. (OTCQB:VNTH)
Over the last three months Vantage, and its parent company, has been developing version 2.0 of its sensor technology. Version 2.0 operates on a Bluetooth platform eliminating the need for physical connections to multiple smartphone platforms. The new sensor is wirelessly compatible with all devices that have Bluetooth capability and will also operate with tablet technology. Version 2.0 of the sensor has the capacity to be scaled up to 256 sensor channels.
Recently, molecular samples analyzed by the Vantage Sensor 2.0 were sent to a third party laboratory specializing in analytical, environmental and pharmacological testing. When testing for lower and higher concentrations of certain molecules, which are important biomarkers in disease detection, results suggested that the sensor may actually be more sensitive than Gas Chromatography–Mass Spectrometry (GC-MS). A GC-MS is considered the gold standard for molecular analysis typically costing as much as six figures. Vantage plans to retail this sensor for less than $200.
A provisional patent was filed recently to protect the proprietary algorithm used to convert the nano-sensor data into useful calibrated measurements. The key inventor, formerly a NASA contractor, has been engaged to help imbed the algorithm into hand-held apps that communicate directly with the new Bluetooth device. The Company also recruited two additional staff members; a Chief Scientist for Nanotechnology who brings 10 years of experience and a Chief Technology Officer who brings 16 years of experience.
The Company and its partners have just completed version 3.0 of a breath capture device, which attaches directly onto the sensor. The breath capture device allows for unlim
Life Sciences Report - George Zavoico of MLV & Co likes CTSO
GZ: I want to mention CytoSorbents Corp. (CTSO:OTCBB). It's a small company that developed a cartridge called CytoSorb, which contains beads that can filter a number of cytokines from patients who have sepsis, trauma and burns. These "cytokine storms" are the result of a systemic inflammatory response that occurs in very sick patients. CytoSorb is CE-marked in Europe, which is the equivalent of FDA device clearance in the U.S., and is being used in Europe.
The product requires no learning curve: Doctors just put the cartridge in a blood dialysis system or in a cardiopulmonary bypass circuit. That's it. I think it's in use in more than 30 countries now. There are also a number of ISTs with CytoSorb going on in Europe. The company's recent revenue growth is impressive. CytoSorbents plans to start a trial in cardiac surgery in the U.S. A small trial in Germany demonstrated that the use of CytoSorb with a heart-lung machine in high-risk cardiac surgery reduced blood levels of proinflammatory cytokines and inflammatory biomarkers in a three-day post-operative period. If CytoSorb gets approved in the U.S., we could see a big uptick in revenue and the value of the company.
What's impressive about CytoSorb are numerous case studies coming out of Europe where the use of the cartridge induces a rapid reversal of multiorgan failure in sepsis or traumatic shock, with full recovery of the patients. We see CytoSorb gaining traction in territories where a CE-Mark is sufficient to launch a product.
AEMD is doing this for EBOLA patients in America ,how many people die of sepsis every day. Cytosorbents could get in the news very fast with Doctors using it for compassionate use in America, plus more data.